Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. Gritstone’s approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. They believe that activating and directing the immune system to these tumor targets could offer an important opportunity to extend the benefits of immunotherapy for patients with cancer. To learn more about Gritstone's approach, please view the video below.

Gritstone Oncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts and Pleasanton, California. They were founded in August 2015 and are listed on the Nasdaq Global Select Market under the ticker symbol GRTS.